A community that understands
The Triple Negative Breast Cancer Foundation offers TNBC education and community resources for patients and loved ones.
Visit the TNBC Foundation ↗Information for your care-team discussion · Not medical advice. Live registry results are search candidates, not confirmed eligibility or available slots. Use the registry criteria and your oncology team to confirm whether a study fits.
Explore your options
Your live trial matches
Live ClinicalTrials.gov records, with biomarker and mutation filters.
Your biomarkers or mutations
Select findings from your report or topics you want to explore. These filters find mentions in registry text; they do not confirm a qualifying mutation, test cutoff, or accepted cancer type.
Exact phrase after punctuation is removed. A gene and variant written separately may be missed. No names or other personal information.
The specific gene / mutation phrase, if entered, must also appear.
Separate terms with commas, semicolons, or new lines (up to 500 characters). Hides a trial if any whole word or phrase appears in its title, summaries, eligibility, conditions, or intervention names. Case and punctuation are ignored. Mentions in exclusions also count, so this may hide relevant trials.
Treatment preference
Based on recognized intervention names, including comparison arms. Investigational agents may be unclassified. A category is not a treatment recommendation.
All results below are real registry records. Biomarker mentions can appear in inclusion or exclusion criteria; confirm the relevant cohort with your care team.
Live registry connection
Connecting to the registry...
Weekly monitoring and email alerts are not enabled on this website.
Search scope: registry text mentioning TNBC / triple-negative and metastatic / advanced. Mixed-stage or mixed-cancer studies may appear. This does not cover every tumor-agnostic study; confirm the relevant cohort and local availability.
Explore trial groups
First-in-human means an intervention is being tested in people for the first time. We flag explicit wording in the registry title or current-study description—not Phase 1 alone. “Other / not specified” can include unlabelled first-in-human research; it does not establish prior human experience. Vaccine trials have a recognized vaccine name in their listed interventions; investigational code names may be missed. Vaccine and first-in-human groups can overlap. Counts reflect your current filters.
Ways to make your shortlist more useful
Start with recruiting status and study phase. Use the phase filter above to review Phase 2 or Phase 3 studies separately. Phase 1/2 studies appear under both Phase 1 and Phase 2.
Then check location, prior treatments, and brain-metastasis criteria. These can be more decisive than a biomarker mention. Open the record to check the relevant cohort and a location you can reach.
Keep biomarker filtering focused. A gene can be mentioned in an exclusion criterion. Requiring all selected biomarkers may miss trials that require only one relevant finding.
NCI’s guide to narrowing clinical trials ↗What is new or updated?
New means first posted on ClinicalTrials.gov. Updated means an older record was updated; newly posted records appear only under New. Uses today and the previous 29 calendar days (UTC). An update does not necessarily mean new slots or changed eligibility. Counts reflect the other filters and trial group. Results are sorted by the relevant posting date, newest first.
Find locations you can travel to
Explore sites for your matching trials. Choose a country or state, or zoom into an area and search there.
Recruiting sites only excludes sites with missing status. Confirm openings directly with the site.
Locations will appear when the registry loads.
Numbers on the map show matching trials at that coordinate. Some registry coordinates represent a city rather than an exact facility. Locations without coordinates remain in the trial list unless you restrict the map area. Map tiles are provided by OpenStreetMap; your biomarker and eligibility selections are not sent to the map provider. Report a map issue